Processa Pharmaceuticals, Inc. (PCSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
PCSA Stock Price Chart Interactive Chart >
PCSA Price/Volume Stats
|Current price||$2.52||52-week high||$8.99|
|Prev. close||$2.52||52-week low||$1.50|
|Day high||$2.56||Avg. volume||33,622|
|50-day MA||$2.77||Dividend yield||N/A|
|200-day MA||$4.86||Market Cap||39.91M|
Processa Pharmaceuticals, Inc. (PCSA) Company Bio
Processa Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. Processa Pharmaceuticals serves patients in the United States.
Most Popular Stories View All
PCSA Latest News Stream
|Loading, please wait...|
PCSA Latest Social Stream
View Full PCSA Social Stream
Latest PCSA News From Around the Web
Below are the latest news stories about Processa Pharmaceuticals Inc that investors may wish to consider to help them evaluate PCSA as an investment opportunity.
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and
Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Clinical Drug Pipeline is Funded and Targeting Major Milestones mid-2022 HANOVER, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announces financial results for the quarter ended September 30, 2021, and provides a corporate update. Dr. David
Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis
Next Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine.24-48 hours after PCS6422 administration, 5-FU potency based on systemic exposure per mg of capecitabine was at least 50 x greater than reported for FDA approved capecitabine.The improved metabolism profile and increased potency did not exist 7 days after PCS6422 administration.The timeline of DPD inhibition and
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
HANOVER, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that the Company will report financial results for the quarter ended September 30, 2021 on Thursday November 11, 2021. The Company will host a conference call at 5:30 p.m. Eastern Time on Thursday November
PCSA Price Returns